Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Patterns of Outpatient IVIG Use before and during the COVID Pandemic in Patients with Multiple Myeloma

Jonathan Lambird, John T Mckay, Meng-Yun Lin, Lindsey Abdelfattah, Manisha Bhutani, Barry Paul, Peter M. Voorhees, Cindy Varga, Shebli Atrash, David Duane Hurd

Blood (2023) 142 (Supplement 1): 6634.

https://doi.org/10.1182/blood-2023-180345

Published: 2023

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4401–4404.

https://doi.org/10.1182/blood-2022-167008

Published: 2022

Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2022) 140 (Supplement 1): 4834–4838.

https://doi.org/10.1182/blood-2022-162741

Published: 2022

Journal Articles

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Lawrence D Kaplan, MD, Matthew J. Maurer, MS, Wendy Stock, MD, Nancy L. Bartlett, MD, Noreen Fulton, BS, Adam Pettinger, John C. Byrd, MD, Kristie A. Blum, MD, Ann S. LaCasce, MD MSc, David Duane Hurd, MD, Amy S. Ruppert, MAS, PhD, Francisco J. Hernandez-Ilizaliturri, MD, John P. Leonard, MD, Bruce Cheson, MD

Blood (2018) 132 (Supplement 1): 146.

https://doi.org/10.1182/blood-2018-99-112655

Published: 2018

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Keren Osman, MD, Kristy L. Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, Jennifer MacLean, RN, OCN, Diane Winans, CCRP, Dominic Moore, PhD, John Strader, PA-C, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2011) 118 (21): 3985.

https://doi.org/10.1182/blood.V118.21.3985.3985

Published: 2011

Journal Articles

Altered Lipid and Mitochondrial Metabolism Are Viable Targets in Acute Leukemia,

Timothy Pardee, MD, PhD, Laura M DeFord-Watts, PhD, Erica Peronto, BS, Denise A Levitan, MD, David Duane Hurd, MD, Steven Kridel, PhD

Blood (2011) 118 (21): 3618.

https://doi.org/10.1182/blood.V118.21.3618.3618

Published: 2011

Journal Articles

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Blood (2010) 116 (21): 1376.

https://doi.org/10.1182/blood.V116.21.1376.1376

Published: 2010

Journal Articles

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Philip L. McCarthy, MD, Kouros Owzar, PhD, Kenneth C. Anderson, Craig C. Hofmeister, MD, David Duane Hurd, MD, Hani Hassoun, MD, Sergio Giralt, MD, Edward A. Stadtmauer, MD, Paul G Richardson, MD, Daniel J. Weisdorf, MD, Ravi Vij, MBBS, MD, Jan S Moreb, MD, Natalie Scott Callander, MD, Koen Van Besien, MD, Teresa Gentile, MD, PhD, Luis Isola, MD, Richard T Maziarz, MD, Don A. Gabriel, MD, PhD, Asad Bashey, MD, PhD, Heather Landau, MD, Thomas Martin, MD, Muzaffar H. Qazilbash, MD, Denise Levitan, MD, Brian McClune, MD, Vera Hars, MS, John Postiglione, BA, Chen Jiang, PhD, Elizabeth Bennett, BS, Susan S Barry, BA, Linda Bressler, PharmD, Michael Kelly, MA, Michele Sexton, MS, Cara Rosenbaum, MD, Hari Parameswaran, MD, MS, Marcelo C Pasquini, MD, MS, Mary M. Horowitz, MD, MS, Thomas C. Shea, MD, Steven M Devine, MD, Charles Linker, MD

Blood (2010) 116 (21): 37.

https://doi.org/10.1182/blood.V116.21.37.37

Published: 2010

Journal Articles

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, M.D., Cristina Gasparetto, MD, Keren Osman, MD, Kristy Richards, PhD, MD, Madlyn Ferraro, RN, OCN, CCRC, Reynaldo Garcia, RN, OCN, Jennifer MacLean, RN, Diane Winans, Dominic Moore, PhD, John Strader, Robert Z. Orlowski, MD, PhD, David Duane Hurd, MD

Blood (2010) 116 (21): 1955.

https://doi.org/10.1182/blood.V116.21.1955.1955

Published: 2010

Journal Articles

Possible Role of Engraftment Syndrome in Myelodysplastic Syndrome after Autologous Transplants.

Yi Kong Keung, MD, Michael W Beaty, Mark Pettenati, Denise Levitan, MD, Istvan Molnar, MD, Mohan C. Thakuri, MD, Julia Cruz, MD, David Duane Hurd, MD

Blood (2008) 112 (11): 2156.

https://doi.org/10.1182/blood.V112.11.2156.2156

Published: 2008

Journal Articles

High Dose Cytarabine and Clofarabine (HiDAC → CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.

Bayard Powell, Ralph D’Agostino, Jr., PhD, Denise Levitan, MD, Leslie Renee Ellis, MD, Susan Lyerly, PA-C, Megan Skiles, PA-C, Megan Manuel, NP, Robin Harrelson, RN, Claire Kimbrough, David Duane Hurd, MD

Blood (2008) 112 (11): 1936.

https://doi.org/10.1182/blood.V112.11.1936.1936

Published: 2008

Journal Articles

Limited Phase I Trial of Sequential High Dose Cytarabine and Clofarabine (HiDAC→CLOF) in Relapsed or Refractory Acute Myeloid Leukemia.

Bayard L. Powell, MD, James Lovato, PhD, Claire Kimbrough, Susan Lyerly, PA-C, Sonya Galloway-Daniels, NP, Cathy Motley, RN, Robin Harrelson, RN, Yi Kong Keung, MD, Mohan C. Thakuri, MD, Istvan Molnar, MD, Denise Levitan, MD, David Duane Hurd, MD

Blood (2006) 108 (11): 4565.

https://doi.org/10.1182/blood.V108.11.4565.4565

Published: 2006

Journal Articles

Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.

Lloyd E. Damon, MD, Jeff Johnson, Donna Niedzwiecki, Bruce D. Cheson, MD, David Duane Hurd, MD, Nancy L. Bartlett, MD, John C. Byrd, Michael Kelly, Charles Linker, MD, George P. Canellos, MD

Blood (2006) 108 (11): 2737.

https://doi.org/10.1182/blood.V108.11.2737.2737

Published: 2006

NARROW

Patterns of Outpatient IVIG Use before and during the COVID Pandemic in Patients with Multiple Myeloma

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Bortezomib Maintenance (BM) or Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): 8 Year Follow up of CALGB 50403 (Alliance)

Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study,

Altered Lipid and Mitochondrial Metabolism Are Viable Targets in Acute Leukemia,

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma

Possible Role of Engraftment Syndrome in Myelodysplastic Syndrome after Autologous Transplants.

High Dose Cytarabine and Clofarabine (HiDAC → CLOF) in Relapsed or Refractory Acute Myeloid Leukemia, a Phase 2 Trial.

Limited Phase I Trial of Sequential High Dose Cytarabine and Clofarabine (HiDAC→CLOF) in Relapsed or Refractory Acute Myeloid Leukemia.

Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only